Welcome to the Boehringer Ingelheim Pharmaceutical Inc (BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.
On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.
By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. The following steps are required in order to process your grant request through our on-line grant management portal:
Medical Education Grants
A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.
Please see below for submission timelines:
- Grant applications with total program costs/expenses of $10,000.00 or less, must be submitted no less than 60 days prior to the program start date.
- Grant applications with total program costs/expenses greater than $10,000.00, must be submitted no less than 90 days prior to the program start date.
New and Returning Visitors to BIPI/Lilly Medical
Grants
To begin a new application, return to a saved application, or
track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/.
If this is the first time you are visiting the site, you must register as a New
User. An application ID beginning with "ME", will be assigned once you submit
the application.
Educational Objectives
- Describe the mechanisms of action and clinical data describing the safety and efficacy of available and emerging therapies including incretin-based therapies in T2DM patients with microvascular and/or macrovascular complications.
- Outline the morbidity, mortality and cost burdens that result from inadequate management of T2DM and its resultant complications in diverse populations (race, ethnicity, gender and age etc).
- Describe the role of aggressive, multifaceted approaches to attaining treatment goals including glycemic control and controlling weight, in relation to microvascular and/or macrovascular complications.
- Enhance awareness of risk factors for declining renal function in at-risk patients with T2DM and emphasize the importance of early recognition and diagnosis of renal impairment and appropriate glycemic management in such patients.
- Discuss strategies to align practice guidelines and consensus recommendations with current standards of care and to apply these appropriately for the care of patients with T2DM to optimize clinical outcomes.
- Discuss new models of care in the management of T2DM which may assist providers in delivering improved patient care and educate patients on the importance of self-management of their disease.
_______________________________________________________________________________________________________________________________
- Describe the mechanisms of action and basic/clinical data describing the safety and efficacy of emerging therapies for use in T2DM patients, including emerging therapies for T2DM in late phase development.
- Outline the morbidity, mortality and cost burdens that result from inadequate management of T2DM and its resultant complications.
- Examine and describe the role of evolving standards of care and multifaceted approaches to attaining treatment goals including glycemic control and controlling weight, in relation to microvascular and/or macrovascular complications and how clinicians can overcome clinical inertia.
- Discuss clinical strategies to appropriately incorporate new therapeutic classes and agents into practice recommendations for the care of patients with T2DM to optimize clinical outcomes.
Responding to a Request for Educational Grant Application
(REGA)
Throughout the year, the Medical Grants department may announce a
Request for Educational Grant Application (REGA). The intent of this
announcement is to notify experienced and accredited Continuing Medical
Education (CME) providers and accredited Continuing Education (CE) providers
that BIPI/Lilly is interested in receiving applications for educational grants
for support consideration.
Grant applications in response to BIPI/Lilly
Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi.
While REGAs may specify timing of requested responses, BIPI and Lilly will
continue to review all grant requests which are received.
To contact the
BIPI/Lilly Alliance Medical Grants Department, please call (800) 295-0717. (8:00
a.m. - 5:00 p.m. EST, Monday – Friday)
| | |
 |
 |
| Copyright © 2011 Boehringer Ingelheim Pharmaceuticals, Inc All rights reserved. | |